Education
About Us
Working with TipRanks
Follow Us
SinoMab Bioscience Ltd. (HK:3681)
:3681
Total Valuation
SinoMab Bioscience Ltd. has a market cap or net worth of HK$2.74B. The enterprise value is HK$2.58B.
Market CapHK$2.74B
Enterprise ValueHK$2.58B
Share Statistics
SinoMab Bioscience Ltd. has 1,386,638,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,386,638,300
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
SinoMab Bioscience Ltd.’s return on equity (ROE) is -0.96 and return on invested capital (ROIC) is -23.90%.
Return on Equity (ROE)-0.96
Return on Assets (ROA)-0.25
Return on Invested Capital (ROIC)-23.90%
Return on Capital Employed (ROCE)-0.29
Revenue Per Employee21.33K
Profits Per Employee-1.95M
Employee Count95
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of SinoMab Bioscience Ltd. is ―. SinoMab Bioscience Ltd.’s PEG ratio is 0.20.
PE Ratio―
PS Ratio542.51
PB Ratio5.70
Price to Fair Value5.70
Price to FCF-6.38
Price to Operating Cash Flow-13.61
PEG Ratio0.20
Income Statement
In the last 12 months, SinoMab Bioscience Ltd. had revenue of 2.03M and earned -185.14M in profits. Earnings per share was -0.17.
Revenue2.03M
Gross Profit543.00K
Operating Income-161.35M
Pretax Income-185.14M
Net Income-185.14M
EBITDA-142.79M
Earnings Per Share (EPS)-0.17
Cash Flow
In the last 12 months, operating cash flow was -87.12M and capital expenditures 28.10M, giving a free cash flow of -59.02M billion.
Operating Cash Flow-87.12M
Free Cash Flow-59.02M
Free Cash Flow per Share-0.04
Dividends & Yields
SinoMab Bioscience Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.22
52-Week Price Change30.15%
50-Day Moving Average2.47
200-Day Moving Average1.73
Relative Strength Index (RSI)41.31
Average Volume (3m)14.30M
Important Dates
SinoMab Bioscience Ltd. upcoming earnings date is Mar 23, 2026, TBA (Not Confirmed).
Last Earnings DateAug 29, 2025
Next Earnings DateMar 23, 2026
Ex-Dividend Date―
Financial Position
SinoMab Bioscience Ltd. as a current ratio of 0.91, with Debt / Equity ratio of 250.00%
Current Ratio0.91
Quick Ratio0.91
Debt to Market Cap0.38
Net Debt to EBITDA-2.94
Interest Coverage Ratio-18.63
Taxes
In the past 12 months, SinoMab Bioscience Ltd. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
SinoMab Bioscience Ltd. EV to EBITDA ratio is -10.64, with an EV/FCF ratio of -8.82.
EV to Sales750.00
EV to EBITDA-10.64
EV to Free Cash Flow-8.82
EV to Operating Cash Flow-11.62
Balance Sheet
SinoMab Bioscience Ltd. has HK$143.10M in cash and marketable securities with HK$408.11M in debt, giving a net cash position of -HK$265.02M billion.
Cash & Marketable SecuritiesHK$143.10M
Total DebtHK$408.11M
Net Cash-HK$265.02M
Net Cash Per Share-HK$0.19
Tangible Book Value Per ShareHK$0.18
Margins
Gross margin is 26.80%, with operating margin of -7964.22%, and net profit margin of -9138.25%.
Gross Margin26.80%
Operating Margin-7964.22%
Pretax Margin-9138.25%
Net Profit Margin-9138.25%
EBITDA Margin-7047.98%
EBIT Margin-7992.40%
Analyst Forecast
The average price target for SinoMab Bioscience Ltd. is HK$3.50, which is 11.43% higher than the current price. The consensus rating is Hold
Price TargetHK$3.50
Price Target Upside90.22% Upside
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast-100.00%
EPS Growth Forecast30.68%